EHA Library - The official digital education library of European Hematology Association (EHA)

PHASE I OPEN-LABEL SINGLE ARM STUDY OF GPRC5D CAR-T CELLS (ORICAR-017) IN PATIENTS WITH RELAPTSED/REFRACTORY MULTIPLE MYELOMA (POLARIS)
Author(s): ,
Mingming Zhang
Affiliations:
Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University,Hangzhou,Chine;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University,Hangzhou,China;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University,Hangzhou,Cina;Bone Marrow Transplantation Center,
,
Yongxian Hu
Affiliations:
Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University,Hangzhou,Chine;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University,Hangzhou,China;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University,Hangzhou,Cina;Bone Marrow Transplantation Center,
,
Xiaomin Ding
Affiliations:
Oricell Therapeutics Co., Ltd,Shanghai,Chine;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,Cina;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,Ki
,
Yu Tang
Affiliations:
Oricell Therapeutics Co., Ltd,Shanghai,Chine;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,Cina;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,Ki
,
Yue Yang
Affiliations:
Oricell Therapeutics Co., Ltd,Shanghai,Chine;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,Cina;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,Ki
,
Siye Chen
Affiliations:
Oricell Therapeutics Co., Ltd,Shanghai,Chine;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,Cina;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,China;Oricell Therapeutics Co., Ltd,Shanghai,Ki
He Huang
Affiliations:
Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University,Hangzhou,Chine;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University,Hangzhou,China;Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University,Hangzhou,Cina;Bone Marrow Transplantation Center,
(Abstract release date: 05/26/22) EHA Library. Huang H. 06/11/22; 357127; S263
He Huang
He Huang
Contributions
Abstract
Presentation during EHA2022: All Oral presentations will be presented between Friday, June 10 and Sunday, June 12 and will be accessible for on-demand viewing from Monday, June 20 until Monday, August 15, 2022 on the Congress platform.

Abstract: S263

Type: Oral Presentation

Session title: Gene therapy and cellular immunotherapy - Clinical 2

Background
G-protein–coupled receptor class 5-member D (GPRC5D), a type-C 7-pass transmembrane receptor protein, is predominantly expressed on malignant plasma cell phenotype, including most malignant plasma cells from pts with multiple myeloma (MM).

The autologous GPRC5D-directed CAR-T cell (OriCAR-017), owning to an additional proprietary Ori element, is the standard second generation CAR-T cell with improvement in expansion and durability of CAR-T cells post-transfusion.

Here we report initial results from the phase I open-label single arm study of GPRC5D CAR-T Cells (OriCAR-017) in pts with Relapsed/Refractory (R/R) MM (NCT05016778).

Aims
The primary objective in the dose escalation phase was to evaluate safety and tolerability of OriCAR-017.  Secondary endpoints included efficacy and pharmacokinetics (expansion and persistence of OriCAR-017.

Methods
Key enrolment criteria included adults with measurable MM, R/R or intolerant to established MM therapies, prior BCMA-targeted therapy allowed. Patient received lymphodepleting chemotherapy with Fludarabine 30mg/m2 daily and cyclophosphamide 300mg/m2 daily for 3 days followed by a single infusion of OriCAR-017. The trial followed a standard 3+3 design with the following dose cohorts: 1×106/kg, 3×106/kg and 6×106/kg CAR+ T cells. 

Results

Eleven pts with R/R MM were enrolled and underwent apheresis during June 9, 2021 and February 25, 2022. Nine of them have completed OriCAR-017 infusion to date. 2 pts were suspended infusion due to rapid disease progression.

Of the 9 pts infused, median age of 65 years (range: 41-71) and a median of 6 (range 3-17) prior lines of therapy; 4 (44.4%) prior BCMA CART therapy. 3 (33.3%) pts with extramedullary plasmacytoma ≥ 1 and 7 (77.8%) pts with bone marrow plasma cells ≥60% at baseline. Five out of 6 pts had high-risk cytogenetic profiles, including 2 pts with del(17p).

No dose-limiting toxicities occurred. The most common treatment-related AEs were hematological toxicities. All pts experienced Cytokine Release Syndrome (CRS, with 8(88.9%) pts in G1, 1 (11.1%) patient in G2), no G3/4 CRS was observed. All CRS cases were rapidly relieved after conventional CRS intervention, including tocilizumab and steroids. No neurologic toxicities were reported to date. 

All 9pts median follow up time was 118 days (range33—220). A 100.0% ORR were observed with 3 (33.3%) pts achieved CR/sCR, 3 pts (33.3%) were VGPR, 3 pts were PR (33.3%).   4 pts relapsed from BCMA CAR-T therapy had responses with 1 sCR, 2 VGPR, 1 PR. All 9 pts were Minimal Residual Disease (MRD) negative in the bone marrow by flow cytometry (sensitivity: 10-5) at day 28 after infusion, and 6pts continued MRD negative at month 3 and 2 pts at month 6 after infusion.

Robust OriCAR-017 expansion in peripheral blood by using qPCR in 3 dose cohorts, median peak was 349866.1copies/ml (range 60837.5 – 2240358.5), median time to peak expansion was 10 days (range 7-14).  8 out of 9 patients detected CAR + cell in bone marrow at D28 after infusion with median 498048.3copies/ml (range 495.4- 2358538.6).

Conclusion
In this phase I study, OriCAR-017 was safe and showed impressive efficacy among previously heavily treated R/RMM pts.  Majority of AEs were transient, manageable, and reversible. 100% ORR and 100% MRD negative rate, along with favorable safety evidenced support OriCAR-017 could be a competitive therapy for pts with R/RMM. Furthermore, pts who had relapsed from BCMA CAR-T therapy may still benefit from OriCAR-017 treatment.

Keyword(s): CAR-T, Multiple myeloma, Phase I



© 2022 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2022 ASCO Annual Meeting. All rights reserved.
Presentation during EHA2022: All Oral presentations will be presented between Friday, June 10 and Sunday, June 12 and will be accessible for on-demand viewing from Monday, June 20 until Monday, August 15, 2022 on the Congress platform.

Abstract: S263

Type: Oral Presentation

Session title: Gene therapy and cellular immunotherapy - Clinical 2

Background
G-protein–coupled receptor class 5-member D (GPRC5D), a type-C 7-pass transmembrane receptor protein, is predominantly expressed on malignant plasma cell phenotype, including most malignant plasma cells from pts with multiple myeloma (MM).

The autologous GPRC5D-directed CAR-T cell (OriCAR-017), owning to an additional proprietary Ori element, is the standard second generation CAR-T cell with improvement in expansion and durability of CAR-T cells post-transfusion.

Here we report initial results from the phase I open-label single arm study of GPRC5D CAR-T Cells (OriCAR-017) in pts with Relapsed/Refractory (R/R) MM (NCT05016778).

Aims
The primary objective in the dose escalation phase was to evaluate safety and tolerability of OriCAR-017.  Secondary endpoints included efficacy and pharmacokinetics (expansion and persistence of OriCAR-017.

Methods
Key enrolment criteria included adults with measurable MM, R/R or intolerant to established MM therapies, prior BCMA-targeted therapy allowed. Patient received lymphodepleting chemotherapy with Fludarabine 30mg/m2 daily and cyclophosphamide 300mg/m2 daily for 3 days followed by a single infusion of OriCAR-017. The trial followed a standard 3+3 design with the following dose cohorts: 1×106/kg, 3×106/kg and 6×106/kg CAR+ T cells. 

Results

Eleven pts with R/R MM were enrolled and underwent apheresis during June 9, 2021 and February 25, 2022. Nine of them have completed OriCAR-017 infusion to date. 2 pts were suspended infusion due to rapid disease progression.

Of the 9 pts infused, median age of 65 years (range: 41-71) and a median of 6 (range 3-17) prior lines of therapy; 4 (44.4%) prior BCMA CART therapy. 3 (33.3%) pts with extramedullary plasmacytoma ≥ 1 and 7 (77.8%) pts with bone marrow plasma cells ≥60% at baseline. Five out of 6 pts had high-risk cytogenetic profiles, including 2 pts with del(17p).

No dose-limiting toxicities occurred. The most common treatment-related AEs were hematological toxicities. All pts experienced Cytokine Release Syndrome (CRS, with 8(88.9%) pts in G1, 1 (11.1%) patient in G2), no G3/4 CRS was observed. All CRS cases were rapidly relieved after conventional CRS intervention, including tocilizumab and steroids. No neurologic toxicities were reported to date. 

All 9pts median follow up time was 118 days (range33—220). A 100.0% ORR were observed with 3 (33.3%) pts achieved CR/sCR, 3 pts (33.3%) were VGPR, 3 pts were PR (33.3%).   4 pts relapsed from BCMA CAR-T therapy had responses with 1 sCR, 2 VGPR, 1 PR. All 9 pts were Minimal Residual Disease (MRD) negative in the bone marrow by flow cytometry (sensitivity: 10-5) at day 28 after infusion, and 6pts continued MRD negative at month 3 and 2 pts at month 6 after infusion.

Robust OriCAR-017 expansion in peripheral blood by using qPCR in 3 dose cohorts, median peak was 349866.1copies/ml (range 60837.5 – 2240358.5), median time to peak expansion was 10 days (range 7-14).  8 out of 9 patients detected CAR + cell in bone marrow at D28 after infusion with median 498048.3copies/ml (range 495.4- 2358538.6).

Conclusion
In this phase I study, OriCAR-017 was safe and showed impressive efficacy among previously heavily treated R/RMM pts.  Majority of AEs were transient, manageable, and reversible. 100% ORR and 100% MRD negative rate, along with favorable safety evidenced support OriCAR-017 could be a competitive therapy for pts with R/RMM. Furthermore, pts who had relapsed from BCMA CAR-T therapy may still benefit from OriCAR-017 treatment.

Keyword(s): CAR-T, Multiple myeloma, Phase I



© 2022 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2022 ASCO Annual Meeting. All rights reserved.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies